MIA SH3 domain containingGenealiases: CD-RAP · MIA1
Q-omics provides the consensus-scored MIA profile across patient tissues and cancer cell-line models. MIA expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIA is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, MIA RNA expression shows 13,043 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BRCA, and TGCT as cancer lineages where MIA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIA survival associations across molecular data types. MIA RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIA RNA expression–survival associations across cancer types. High MIA expression shows unfavorable associations in KIRC, LGG and LIHC, but favorable associations in HNSC, BRCA and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIA RNA expression.
This table summarizes MIA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIA shows lower tumor expression in BRCA and HNSC and higher tumor expression in LUSC, PAAD, ESCA and LUAD. The BRCA box plot shows higher MIA RNA expression in normal versus tumor tissue (log2 FC = −2.355, t-test p < 0.001).
This table shows molecular features associated with MIA in patient tissues and cancer cell lines. In patient samples, MIA shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MIA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
